– Company plans to file IND for Ziopharm TCR-T program in Q1 of next year for its Library “hotspot” trial – – Eden BioCell on track for IND filing i n Taiwan for autologus CAR-T clinical trial this year based on rapid personalized manufacturing ; several patients dosed under compassionate
Urges Shareholders to Sign and Return Ziopharm’s GREEN Consent Revocation Card Emphasizes that Substantial Board Refr eshment is Already in Process Reiterates Commitment to Implementing Strategy and Delivering Significant Value to S hareholders Questions WaterMill’s Attempt to Seize Outsize d
BOSTON , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, November 5 , at 4:30 pm EDT to provide a corporate update and discuss financial results for the third quarter ended September 30, 2020
BOSTON , Oct. 16, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that it has received a notice, and acknowledges the filing of, a preliminary consent solicitation statement by WaterMill Asset Management Corp. , Mr. Robert W.
BOSTON , Oct. 01, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the 7 th Annual Jefferies Cell Therapy Virtual Summit on October 5, 2020 at
– Life Sciences industry veteran; 15-year Cephalon executive, serving progressively as CFO, COO and then CEO at time of $6.8 billion acquisition by Teva – – Doug Pagán Steps Down from Board of Directors – BOSTON , Sept. 22, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc.
BOSTON , Sept. 15, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced the appointment of four additional members to its Scientific Advisory Board (SAB). The SAB , under the leadership of Carl June , M.D.
BOSTON , Sept. 14, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to Ad-RTS-hIL-12 with veledimex (Controlled IL-12) for the investigational
BOSTON , Sept. 10, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in two upcoming conferences: H.C. Wainwright 22nd Annual Global Investment Conference Date:
– Enrollment completed in Controlled IL-12 phase 2 clinical trial with Regeneron’s Libtayo ® – – First patient with DIPG dosed in phase 1/2 pediatric brain tumor trial of Contolled IL-12 – – Work restrictions at the NCI and MD Anderson easing; MD Anderson initiated phase 1 CD19-specific CAR-T